08.06.2021
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.
21.05.2021
On the Neutron podcast, CRP apheresis was introduced and explained, and Dr. Ahmed Sheriff was interviewed. The focus was on the use of the therapy in COVID-19 patients.
19.05.2021
The Sat.1 morning show has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
19.05.2021
As part of the Lunch & Learn event series of the Biotechnologieverbund Berlin-Brandenburg (bbb), Dr. Ahmed Sheriff presented the PentraSorb® CRP and reported on its use at Klinikum Havelhöhe, where almost all COVID-19 patients are now treated with CRP apheresis. Afterwards there was an exciting discussion.
Hennigsdorf, 18.05.2021 - Today, the German TV station ZDF reported in detail about the promising CRP apheresis for COVID-19 patients from the medical technology company Pentracor GmbH based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB). At Berlin's Havelhöhe Community Hospital, Pentracor's new therapeutic extracorporeal treatment method is now being used with great success on many severely ill COVID-19 patients.
18.05.2021
ZDF has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
07.05.2021
In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.
The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.
22.04.2021
An article by ntv Wissen reported on the use of CRP apheresis in COVID-19 patients at the Gemeinschaftskrankenhaus Havelhöhe.
You can read the article in German here .
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.
17.04.2021
COVID-19 patients are treated with CRP apheresis at the Klinikum Havelhöhe. This was featured in the rbb Abendschau.
